Evolution of the Average Target: Verastem, Inc.

Evolution of the Average Target - Verastem, Inc.

Evolution of the Target Price: Verastem, Inc.

Evolution of the Target Price - Verastem, Inc.

Changes in Analyst Recommendations: Verastem, Inc.

9f8f79dd50086c093a91dd4c9f0e3ad4.36jQ74up2reK6pS_Nl69X6thxEABdvSvVyaBAnJDLDE.vvfnqbzHsobfmNvWYwrHB5wRlnRFQsHJLh_PbAISSXunxaWAxMyqheCS4w~5f47decfc4644aa745da2538a0f4478e
06/11 RBC Cuts Price Target on Verastem to $18 From $19, Keeps Outperform, Speculative Risk MT
15/10 Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says MT
15/10 Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating MT
15/10 RBC Raises Price Target on Verastem to $19 From $14, Keeps Outperform, Speculative Risk MT
07/10 B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating MT
18/09 Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says MT
17/09 Wolfe Research Initiates Verastem at Outperform MT
11/08 Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating MT
07/07 RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating MT
24/06 Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says MT
14/05 Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating MT
29/04 Mizuho Securities Keeps Verastem Price Target to $16, Maintains Outperform Rating MT
29/04 Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating MT
08/01 RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk MT
05/11 RBC Capital Adjusts Verastem Price Target to $14 From $13, Maintains Outperform Rating MT
19/25/19 Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma CI
26/25/26 B. Riley Raises Price Target on Verastem to $16 From $13, Keeps Buy Rating MT
16/25/16 Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating MT
08/25/08 RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk MT
25/25/25 RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk MT
09/25/09 B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating MT
09/25/09 Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating MT
09/25/09 RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk MT
28/25/28 B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating MT
10/25/10 Jefferies Initiates Verastem at Buy With $15 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+110.54%
+38.3%
+15.44%
+7.53%
+12.65%
+17.64%
+59.48%
+30.16%
+17.66%
+60.27%
Average +36.97%
Weighted average by Cap. +26.69%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.180USD
Average target price
17.22USD
Spread / Average Target
+110.54%
High Price Target
24.00USD
Spread / Highest target
+193.40%
Low Price Target
12.00USD
Spread / Lowest Target
+46.70%

Analyst Consensus Detail

Analyst consensus - Verastem, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Verastem, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock
  4. Consensus Verastem, Inc.